CD274 and neoplasm: In patients with advanced non‐small cell lung cancer (NSCLC) after treatment with PD‐1 inhibitor (pembrolizumab), the exon sequencing results showed that patients with higher tumour neoantigens and less intratumoural heterogeneity had higher PD‐L1 expression, sensitivity to immune checkpoint suppression therapy and longer overall survival time.115